Hosted on MSN2mon
Amgen says obesity drug caused up to 20% weight loss after a year, with no plateau
Amgen said its experimental weight loss injection helped patients lose up to 20% of their weight on average after a year, with no plateau, in a critical mid-stage trial. But shares of Amgen fell ...
pharmaphorum2d
Amgen to acquire deCODE Genetics for US $415 million
Biotechnology company, Amgen, has announced that it has entered into a definitive agreement to acquire deCODE Genetics, a global leader in human genetics, for US $415 million. The all-cash ...
Seeking Alpha7d
Amgen: Multiple Strengths, But The Valuation Is A Concern
Amgen is a biotechnology leader with competitive advantages in scale, R&D, manufacturing efficiency, and distribution, bolstered by a robust pipeline and rising margins. I currently rate Amgen as ...
Yahoo Finance8d
Why Amgen (AMGN) Stock Is Trading Up Today
Shares of biotech company Amgen (NASDAQ:AMGN) jumped 5.3% in the morning session after the company reported strong fourth-quarter results. Amgen exceeded analysts' revenue expectations this ...
Reuters10d
Amgen profits rise, next MariTide studies start by mid-year
MariTide Phase 3 studies to begin in first half of year FDA places hold on AMG 513 obesity drug trial Amgen's Q4 earnings beat estimates, revenue up 11% Feb 4 (Reuters) - Amgen (AMGN.O), opens new ...
Nasdaq9d
Amgen Surpasses Q4 Earnings Forecasts
Biotechnology specialist Amgen (NASDAQ:AMGN) reported fourth-quarter and full-year 2024 earnings on Tuesday, Feb. 4, that topped analysts' consensus estimates. Analysts estimated Q4 adjusted EPS ...